USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Struggling to finance further development of its immunotherapy candidates alone, Jounce Therapeutics has announced plans to merge with British firm Redx Pharma. 23 February 2023
Two more American biotech companies have been forced to announce plans to restructure, including mandatory redundancies, to avoid looming financial trouble. 23 February 2023
French clinical-stage biotech Abivax yesterday announced the successful pricing of an oversubscribed 130 million-euro ($139 million) financing with high-quality US and European biotech specialist investors, adding to the 49 million-euro fundraising in September last year. 23 February 2023
Canadian precision meds company Fusion Pharmaceuticals has announced the acquisition from Texas, USA-based RadioMedix, of the investigational new drug application (IND) for an ongoing Phase II clinical trial. 15 February 2023
Mineralys Therapeutics, a previously private company in the portfolio of HBM Healthcare Investments, successfully completed its IPO last Friday. 13 February 2023
Relief Therapeutics has decided to voluntarily withdraw its planned initial public offering (IPO), the Swiss biopharma company announced today, when its shares dipped 1%. 8 February 2023
Boston, USA-based Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell-based cellular therapies, is $62 million richer. 7 February 2023
After an illustrious career as chief scientific officer at Johnson & Johnson, Dr Paul Stoffels is ready for a new chapter in his home country, with Belgian biotech Galapagos. 2 February 2023
The world’s leading biopharma companies experienced growth in market capitalization of 5.4% on average last year, according to industry analyst GlobalData. 30 January 2023
As global macroeconomic uncertainty hit fundraising across all sectors, investment in UK biotechnology fell from the all-time highs seen in 2021, a new analysis from the industry lobby group UK BioIndustry Association (BIA) and data and insights company Clarivate shows. 26 January 2023
More gloomy news from Finch Therapeutics, as the microbiome company announced it would scrap the Phase III PRISM4 trial of its recurrent C. difficile infection (CDI) candidate CP101. 25 January 2023
A French biotech company claiming to have the first drug that treats the root cause of type 2 diabetes has completed a Series A funding round. 23 January 2023
After a difficult year for investment, look for the biotech industry to engage in creative dealmaking in the market, leading to faster innovation in the lab, Protagonist Therapeutics CEO Dinesh Patel writes in Bio.News. 20 January 2023
Neurodegenerative diseases specialist APRINOIA Therapeutics has announced a merger with Ross Acquisition Corp II, a special purpose acquisition company (SPAC) founded by former US Secretary of Commerce Wilbur Ross. 18 January 2023
French pharma major Sanofi has announced an additional multi-year commitment into its evergreen venture fund, with an increase in capital to more than $750 million. 12 January 2023
US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany’s Bayer, and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi. 10 January 2023
Boston, USA-based Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, has announced the completion of an $85 million financing. 9 January 2023
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news